Form 4: BioAtla CFO Richard Waldron Reports Routine Share Disposition for Tax Obligations Following RSU Vesting

BioAtla, Inc.'s Chief Financial Officer, Richard A. Waldron, reported the disposition of 2,371 common shares to satisfy tax withholding obligations related to the vesting of previously granted restricted stock units.

Summary

• Richard A. Waldron, Chief Financial Officer of BioAtla, Inc. (BCAB), reported a transaction on May 31, 2025, as detailed in a Form 4 filing.
• The transaction involved the disposition of 2,371 shares of BioAtla Common Stock.
• This disposition was not a discretionary sale by Mr. Waldron but rather shares withheld by BioAtla to cover income tax and withholding obligations associated with the vesting and net settlement of previously reported restricted stock units.
• The shares were valued at $0.409 per share for the purpose of tax withholding.
• Following this transaction, Mr. Waldron beneficially owns 340,892 shares of BioAtla Common Stock, which includes shares purchased under the Issuer's Employee Stock Purchase Plan (ESPP).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While shares were 'disposed,' it was for a routine tax withholding related to RSU vesting, which implies a positive event (RSU vesting) for the executive. It's a standard, non-discretionary transaction.

Positives

• The transaction indicates the vesting of previously granted restricted stock units (RSUs), which is a positive event for the employee as it represents compensation becoming exercisable.
• The company is fulfilling its tax obligations on behalf of the employee, indicating adherence to standard corporate governance practices regarding equity compensation.

Negatives

• A reduction of 2,371 shares from the reporting person's direct beneficial ownership, although for tax purposes, means fewer shares are held directly by the executive.

Future Outlook

NA

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically related to equity compensation. It does not provide information on broader industry trends or the competitive landscape within the biotechnology or pharmaceutical sector where BioAtla operates. Such filings are standard for publicly traded companies when executives' equity compensation vests.

Stakeholder Impact

• Shareholders: Minimal direct impact. This is a routine insider transaction for tax purposes and does not indicate a change in the company's operational or financial performance. It slightly reduces the direct ownership of an executive, but the underlying RSU vesting is a positive for the executive.
• Employees: The vesting of RSUs and subsequent tax withholding is a standard part of equity compensation plans, which can be a positive for employee retention and alignment of interests.

Key Dates

Keywords

BioAtla, BCAB, Form 4, SEC Filing, Insider Transaction, Richard Waldron, Chief Financial Officer, CFO, Restricted Stock Units, RSU Vesting, Tax Withholding, Equity Compensation, Beneficial Ownership